The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

被引：28

作者：

Li, Jie ^{[1
]}

Zhu, Jingyu ^{[1
]}

Cao, Biyin ^{[1
]}

Mao, Xinliang ^{[1
]}

机构：

[1] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China

来源：

CURRENT PHARMACEUTICAL DESIGN | 2014年 / 20卷 / 01期

关键词：

Mammalian target of rapamycin ( mTOR); mTOR complex 1; mTOR complex 2; multiple myeloma; drug discovery; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; INCREASES CHEMOSENSITIVITY; CELL-PROLIFERATION; S6; KINASE; CANCER; COMPLEX; DEPTOR; PHOSPHORYLATION;

D O I：

10.2174/13816128113199990638

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The mammalian target of rapamycin ( mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.

引用

页码：125 / 135

页数：11

共 93 条

[61] The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif [J].

Nojima, H ;

Tokunaga, C ;

Eguchi, S ;

Oshiro, N ;

Hidayat, S ;

Yoshino, K ;

Hara, K ;

Tanaka, N ;

Avruch, J ;

Yonezawa, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (18) :15461-15464

[62] Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney [J].

Pearce, Laura R. ;

Sommer, Eeva M. ;

Sakamoto, Kei ;

Wullschleger, Stephan ;

Alessi, Dario R. .

BIOCHEMICAL JOURNAL, 2011, 436 :169-179

[63] Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma [J].

Pene, F ;

Claessens, YE ;

Muller, O ;

Viguié, F ;

Mayeux, P ;

Dreyfus, F ;

Lacombe, C ;

Bouscary, D .

ONCOGENE, 2002, 21 (43) :6587-6597

[64] Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin-associated protein [J].

Peterson, RT ;

Desai, BN ;

Hardwick, JS ;

Schreiber, SL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4438-4442

[65] DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival [J].

Peterson, Timothy R. ;

Laplante, Mathieu ;

Thoreen, Carson C. ;

Sancak, Yasemin ;

Kang, Seong A. ;

Kuehl, W. Michael ;

Gray, Nathanael S. ;

Sabatini, David M. .

CELL, 2009, 137 (05) :873-886

[66] Dynamic Balancing: DEPTOR Tips the Scales [J].

Proud, Christopher G. .

JOURNAL OF MOLECULAR CELL BIOLOGY, 2009, 1 (02) :61-63

[67] Targeting autophagy to fight hematopoietic malignancies [J].

Puissant, Alexandre ;

Robert, Guillaume ;

Auberger, Patrick .

CELL CYCLE, 2010, 9 (17) :3470-3478

[68] Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity [J].

Que, Wenzhong ;

Chen, Junmin ;

Chuang, Ma ;

Jiang, Danrong .

APMIS, 2012, 120 (03) :195-203

[69] Thalidomide in multiple myeloma [J].

Richardson, P ;

Hideshima, T ;

Anderson, K .

BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (03) :115-128

[70] Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo [J].

Roulin, Didier ;

Cerantola, Yannick ;

Dormond-Meuwly, Anne ;

Demartines, Nicolas ;

Dormond, Olivier .

MOLECULAR CANCER, 2010, 9

← 1 2 3 4 5 6 7 8 9 10 →